Search

Your search keyword '"Nguyen, Mindie H."' showing total 2,111 results
Start Over Author "Nguyen, Mindie H."
2,111 results on '"Nguyen, Mindie H."'

1. Racial Disparities in Liver Transplant for Hepatitis C-Associated Hepatocellular Carcinoma

Author

Bennett, Frances J., Keilson, Jessica M., Turgeon, Michael K., Oppat, Kailey M., Warren, Emilie A. K., Shah, Shimul A., Agopian, Vatche G., Magliocca, Joseph F., Cameron, Andrew, Orloff, Susan L., Kubal, Chandrashekhar A., Cannon, Robert M., Akoad, Mohamed E., Emamaullee, Juliet, Aucejo, Federico, Vagefi, Parsia A., Nguyen, Mindie H., Dhanireddy, Kiran, Kazimi, Marwan M., Sonnenday, Christopher J., Foley, David P., Abdouljoud, Marwan, Sudan, Debra L., Humar, Abhinav, Doyle, M. B. Majella, Chapman, William C., and Maithel, Shishir K.

Published
2025
Full Text
View/download PDF

2. Hepatic Resection as the Primary Treatment Method for Hepatocellular Carcinoma After Orthotopic Liver Transplantation

Author

Matar, Abraham J., Oppat, Kailey M., Bennett, Frances J., Warren, Emilie A. K., Wehrle, Chase J., Li, Zhihao, Rajendran, Luckshi, Rokop, Zachary P., Kubal, Chandrashekhar, Biesterveld, Ben E., Foley, David P., Maeda, Mayumi, Nguyen, Mindie H., Elinoff, Beth, Humar, Abhinav, Moris, Dimitrios, Sudan, Debra, Klein, John, Emamaullee, Juliet, Agopian, Vatche, Vagefi, Parsia A., Dualeh, Shukri H. A., Sonnenday, Christopher J., Sapisochin, Gonzalo, Aucejo, Federico N., and Maithel, Shishir K.

Published
2024
Full Text
View/download PDF

4. ASO Visual Abstract: Racial Disparities in Liver Transplant for Hepatitis C-Associated Hepatocellular Carcinoma

Author

Bennett, Frances J., Keilson, Jessica M., Turgeon, Michael K., Oppat, Kailey M., Warren, Emilie A. K., Shah, Shimul A., Agopian, Vatche G., Magliocca, Joseph F., Cameron, Andrew, Orloff, Susan L., Kubal, Chandrashekhar A., Cannon, Robert M., Akoad, Mohamed E., Emamaullee, Juliet, Aucejo, Federico, Vagefi, Parsia A., Nguyen, Mindie H., Dhanireddy, Kiran, Kazimi, Marwan M., Sonnenday, Christopher J., Foley, David P., Abdouljoud, Marwan, Sudan, Debra L., Humar, Abhinav, Doyle, M. B. Majella, Chapman, William C., and Maithel, Shishir K.

Published
2025
Full Text
View/download PDF

5. ASO Visual Abstract: Hepatic Resection as the Primary Treatment Modality for Hepatocellular Carcinoma Following Orthotopic Liver Transplantation

Author

Matar, Abraham J., Oppat, Kailey M., Bennett, Frances J., Warren, Emilie A. K., Wehrle, Chase J., Li, Zhihao, Rajendran, Luckshi, Rokop, Zachary P., Kubal, Chandrashekhar, Biesterveld, Ben E., Foley, David P., Maeda, Mayumi, Nguyen, Mindie H., Elinoff, Beth, Humar, Abhinav, Moris, Dimitrios, Sudan, Debra, Klein, John, Emamaullee, Juliet, Agopian, Vatche, Vagefi, Parsia A., Dualeh, Shukri H. A., Sonnenday, Christopher J., Sapisochin, Gonzalo, Aucejo, Federico N., and Maithel, Shishir K.

Published
2025
Full Text
View/download PDF

9. ASO Author Reflections: Hepatic Resection as the Primary Treatment Modality for Hepatocellular Carcinoma After Orthotopic Liver Transplantation

Author

Matar, Abraham J., Oppat, Kailey M., Bennett, Frances J., Warren, Emilie A. K., Wehrle, Chase J., Li, Zhihao, Rajendran, Luckshi, Rokop, Zachary P., Kubal, Chandrashekhar, Biesterveld, Ben E., Foley, David P., Maeda, Mayumi, Nguyen, Mindie H., Elinoff, Beth, Humar, Abhinav, Moris, Dimitrios, Sudan, Debra, Klein, John, Emamaullee, Juliet, Agopian, Vatche, Vagefi, Parsia A., Dualeh, Shukri H. A., Sonnenday, Christopher J., Sapisochin, Gonzalo, Aucejo, Federico N., and Maithel, Shishir K.

Published
2024
Full Text
View/download PDF

10. Phase 3 Validation of PAaM for Hepatocellular Carcinoma Risk Stratification in Cirrhosis

Author

Fujiwara, Naoto, Lopez, Camden, Marsh, Tracey L., Raman, Indu, Marquez, Cesia A., Paul, Subhojit, Mishra, Sumit K., Kubota, Naoto, Katz, Courtney, Kanzaki, Hiroaki, Gonzalez, Michael, Quirk, Lisa, Deodhar, Sneha, Selvakumar, Pratibha, Raj, Prithvi, Parikh, Neehar D., Roberts, Lewis R., Schwartz, Myron E., Nguyen, Mindie H., Befeler, Alex S., Page-Lester, Stephanie, Srivastava, Sudhir, Feng, Ziding, Reddy, K. Rajender, Khaderi, Saira, Asrani, Sumeet K., Kanwal, Fasiha, El-Serag, Hashem B., Marrero, Jorge A., Singal, Amit G., and Hoshida, Yujin

Published
2025
Full Text
View/download PDF

13. Incidence rates of hepatocellular carcinoma based on risk stratification in steatotic liver disease for precision medicine: A real-world longitudinal nationwide study

Author

Lai, Rongtao, Barnett, Scott, Zhang, Xinrong, Kam, Leslie Yeeman, Cheung, Ramsey, Xie, Qing, and Nguyen, Mindie H.

Subjects
Statistics, Physiological aspects, Complications and side effects, Research, Risk factors, Precision medicine -- Research, Hepatocellular carcinoma -- Statistics -- Risk factors -- Physiological aspects, Medical research, Fatty liver -- Physiological aspects -- Complications and side effects, Medicine, Experimental, Hepatoma -- Statistics -- Risk factors -- Physiological aspects
Abstract

Author(s): Rongtao Lai 1,2, Scott Barnett 1, Xinrong Zhang 1, Leslie Yeeman Kam 1, Ramsey Cheung 1,3, Qing Xie 2, Mindie H. Nguyen 1,4,* Introduction Steatotic liver disease (SLD) is [...], Background Detailed subgroup incidence rates for steatotic liver disease (SLD)-related hepatocellular carcinoma (HCC) are critical to inform practice and public health interventions but remain sparse. We aimed to fill in this gap. Methods and findings In a retrospective cohort study of adults with SLD from the United States (US) Merative Marketscan Research Databases (1/2007 to 12/2021), we estimated HCC incidence stratified by sex, age, cirrhosis, diabetes mellitus (DM), and a combination of all these 4 factors. We excluded patients with significant alcohol use and chronic viral hepatitis. We analyzed data from 741,816 patients with SLD (mean age 51.5 ± 12.8 years, 46% male, 14.7% cirrhosis). During a 2,410,166 person-years (PY) follow-up, 1,740 patients developed HCC. The overall HCC incidence yielded 0.72 per 1,000 PY (95% confidence interval [CI, 0.68, 0.75]). The incidence was higher in males (0.95, 95% CI [0.89, 1.01]) compared to females (0.52, 95% CI [0.48, 0.56]) (p < 0.001). For those with cirrhosis, the incidence was significantly higher at 4.29 (95% CI [4.06, 4.51]) compared to those without cirrhosis (0.14, 95% CI [0.13, 0.16]) (p < 0.001). Additionally, the incidence was higher in patients with DM (1.19, 95% CI [1.12, 1.26]) compared to those without DM (0.41, 95% CI [0.38, 0.44]) (p < 0.001). Chronic kidney disease (CKD) was also associated with a higher HCC incidence of 2.20 (95% CI [2.00, 2.41]) compared to those without CKD (0.58, 95% CI [0.55, 0.62]) (p < 0.001). Similarly, individuals with cardiovascular disease (CVD) had a higher HCC incidence of 1.89 (95% CI [1.75, 2.03]) compared to those without CVD (0.51, 95% CI [0.48, 0.54]) (p < 0.001). Finally, the incidence of HCC was significantly higher in patients with non-liver cancer (3.90, 95% CI [3.67, 4.12]) compared to those without other cancers (0.29, 95% CI [0.26, 0.31]) (p < 0.001). On further stratification, HCC incidence incrementally rose by 10-year age intervals, male sex, cirrhosis, and DM, reaching 19.06 (95% CI [16.10, 22.01]) and 8.44 (95% CI [6.78, 10.10]) in males and females, respectively, but only 0.04 for non-diabetic, noncirrhotic aged Conclusions This nationwide study provided robust granular estimates for SLD-related HCC incidence stratified by several key risk factors. In addition to cirrhosis, future surveillance strategies, prevention, public health initiatives, and future research models should also take into account the impact of sex, age, and DM.

Published
2024
Full Text
View/download PDF

14. Meta‐analysis: Chemoprevention of hepatocellular carcinoma with statins, aspirin and metformin

Author

Zeng, Rebecca W, Yong, Jie Ning, Tan, Darren JH, Fu, Clarissa E, Lim, Wen Hui, Xiao, Jieling, Chan, Kai En, Tan, Caitlyn, Goh, Xin Lei, Chee, Douglas, Syn, Nicholas, Tan, Eunice X, Muthiah, Mark D, Ng, Cheng Han, Tamaki, Nobuharu, Lee, Sung Won, Kim, Beom Kyung, Nguyen, Mindie H, Loomba, Rohit, and Huang, Daniel Q

Subjects
Pharmacology and Pharmaceutical Sciences, Biomedical and Clinical Sciences, Clinical Sciences, Digestive Diseases, Infectious Diseases, Hepatitis, Cancer, Chronic Liver Disease and Cirrhosis, Liver Cancer, Rare Diseases, Liver Disease, Clinical Research, Good Health and Well Being, Humans, Carcinoma, Hepatocellular, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Liver Neoplasms, Aspirin, Metformin, Chemoprevention, hepatoma, incidence, liver cancer, prevention, Gastroenterology & Hepatology, Clinical sciences, Pharmacology and pharmaceutical sciences
Abstract

BackgroundEmerging data suggest that statins, aspirin and metformin may protect against hepatocellular carcinoma (HCC) development. However, prior meta-analyses were limited by heterogeneity and inclusion of studies without adequate adjustment for baseline risks.AimTo examine by an updated meta-analysis the association between these medications and HCC risk.MethodsMedline and Embase databases were searched from inception to March 2022 for studies that balanced baseline risks between study groups via propensity score matching or inverse probability of treatment weighting, that reported the impact of statins, aspirin or metformin on HCC risk. Multivariable-adjusted hazard ratios (HRs) for HCC were pooled using a random effects model.ResultsStatin use was associated with reduced HCC risk overall (HR: 0.52; 95% CI: 0.37-0.72) (10 studies, 1,774,476), and in subgroup analyses for cirrhosis, hepatitis B/C, non-alcoholic fatty liver disease, studies accounting for concurrent aspirin and metformin consumption and lipophilic statins. Aspirin use was associated with reduced HCC risk overall (HR: 0.48; 95% CI: 0.27-0.87) (11 studies, 2,190,285 patients) but not in studies accounting for concurrent statin and metformin use. Metformin use was not associated with reduced HCC risk overall (HR: 0.57; 95% CI: 0.31-1.06) (3 studies, 125,458 patients). Most analyses had moderate/substantial heterogeneity, except in follow-up

Published
2023

15. A multi‐analyte cell‐free DNA–based blood test for early detection of hepatocellular carcinoma

Author

Lin, Nan, Lin, Yongping, Xu, Jianfeng, Liu, Dan, Li, Diange, Meng, Hongyu, Gallant, Maxime A, Kubota, Naoto, Roy, Dhruvajyoti, Li, Jason S, Gorospe, Emmanuel C, Sherman, Morris, Gish, Robert G, Abou‐Alfa, Ghassan K, Nguyen, Mindie H, Taggart, David J, Van Etten, Richard A, Hoshida, Yujin, and Li, Wei

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Digestive Diseases, Rare Diseases, Cancer, Genetics, Prevention, Clinical Research, Liver Disease, Liver Cancer, 4.1 Discovery and preclinical testing of markers and technologies, Detection, screening and diagnosis, 4.2 Evaluation of markers and technologies, Good Health and Well Being, Carcinoma, Hepatocellular, Cell-Free Nucleic Acids, Early Detection of Cancer, Hematologic Tests, Humans, Liver Neoplasms, Prospective Studies, alpha-Fetoproteins, Clinical sciences
Abstract

The limited performance of guideline-recommended abdominal ultrasound and serum alpha-fetoprotein (AFP) highlights the urgent, unmet need for new biomarkers for more accurate detection of early hepatocellular carcinoma (HCC). To this end, we have conducted a prospective clinical validation study to evaluate the performance of the HelioLiver Test, a multi-analyte blood test combining cell-free DNA methylation patterns, clinical variables, and protein tumor markers. A blinded, multicenter validation study was performed with 247 subjects, including 122 subjects with HCC and 125 control subjects with chronic liver disease. The performance of the HelioLiver Test was compared with AFP and the GALAD score as established HCC surveillance blood tests. The performance of the HelioLiver Test (area under the receiver operating characteristic curve [AUROC] = 0.944) was superior to both AFP (AUROC = 0.851; p < 0.0001) and GALAD (AUROC = 0.899; p < 0.0001). Using a prespecified diagnostic algorithm, the HelioLiver Test showed sensitivities of 85% (95% confidence interval [CI], 78%-90%) for HCC of any stage and 76% (95% CI, 60%-87%) for early stage (American Joint Committee on Cancer [AJCC] I and II) HCC. In contrast, AFP (≥20 ng/mL) alone and the GALAD score (≥-0.63) showed lower sensitivities of 62% (95% CI, 54%-70%) and 75% (95% CI, 67%-82%) for HCC overall, and 57% (95% CI, 40%-71%) and 65% (95% CI, 49%-79%) for early stage (AJCC I and II) HCC, respectively. The specificities of the HelioLiver Test (91%; 95% CI, 85%-95%), AFP (97%; 95% CI, 92%-99%), and the GALAD score (94%; 95% CI, 88%-97%) were similar for control subjects. The HelioLiver Test showed superior performance for HCC detection compared to with both AFP and the GALAD score and warrants further evaluation in HCC surveillance settings.

Published
2022

18. Real-world treatment outcome with protease inhibitor direct-acting antiviral in advanced hepatitis C cirrhosis: a REAL-C study

Author

Wong, Yu Jun, Tran, Sally, Huang, Chung-Feng, Hsu, Yao-Chun, Preda, Carmen, Toyoda, Hidenori, Liu, Joanne, Jun, Dae Won, Landis, Charles, Huang, Daniel Q., Gila, Andrei, Negoita, Livia, Yasuda, Satoshi, Tseng, Cheng-Hao, Tsai, Pei-Chien, Uojima, Haruki, Nozaki, Akito, Chuma, Makoto, Atsukawa, Masanori, Ishigami, Masatoshi, Itokawa, Norio, Iio, Etsuko, Lam, Carla Pui-Mei, Watanabe, Tsunamasa, Asai, Akira, Yokohama, Keisuke, Abe, Hiroshi, Enomoto, Masaru, Kawada, Norifumi, Tamori, Akihiro, Lee, Dong Hyun, Jun, Mi Jung, Do, Son, Vo, Dang K. H., Liu, Li, Li, Junyi, Ji, Fanpu, Wang, Wenjun, Li, Yu, Wang, Xiaozhong, Guo, Fen, Xu, Qiang, Jing, Liang, Ye, Qing, Pan, Hongying, Zhang, JiaJie, Wen, Xie, Wang, Qi, Ren, Hong, Cai, Dachuan, Shang, Jia, Liu, Junping, Lu, Chengzheng, Zang, Wenqian, Li, Jia, Niu, Junqi, Zhang, Mingyuan, Wu, Chao, Huang, Rui, Maeda, Mayumi, Nakanishi, Akiko, Yeh, Ming-Lun, Chuang, Wan-Long, Huang, Jee-Fu, Dai, ChiaYen, Ishikawa, Toru, Takaguchi, Koichi, Senoh, Tomonori, Trinh, Huy N., Takahashi, Hirokazu, Eguchi, Yuichiro, Quek, Sabrina Xin Zi, Haga, Hiroaki, Ogawa, Eiichi, Wong, Grace, Buti, Maria, Fukunishi, Shinya, Ueno, Yoshiyuki, Yuen, Man-Fung, Tanaka, Yasuhito, Lim, Seng Gee, Cheung, Ramsey, Yu, Ming-Lung, and Nguyen, Mindie H.

Published
2023
Full Text
View/download PDF

19. An international multidisciplinary consensus on pediatric metabolic dysfunction-associated fatty liver disease

Author

Zhang, Le, El-Shabrawi, Mortada, Baur, Louise A., Byrne, Christopher D., Targher, Giovanni, Kehar, Mohit, Porta, Gilda, Lee, Way Seah, Lefere, Sander, Turan, Serap, Alisi, Anna, Weiss, Ram, Faienza, Maria Felicia, Ashraf, Ambika, Sundaram, Shikha S., Srivastava, Anshu, De Bruyne, Ruth, Kang, Yunkoo, Bacopoulou, Flora, Zhou, Yong-Hai, Darma, Andy, Lupsor-Platon, Monica, Hamaguchi, Masahide, Misra, Anoop, Méndez-Sánchez, Nahum, Ng, Nicholas Beng Hui, Marcus, Claude, Staiano, Amanda E., Waheed, Nadia, Alqahtani, Saleh A., Giannini, Cosimo, Ocama, Ponsiano, Nguyen, Mindie H., Arias-Loste, Maria Teresa, Ahmed, Mohamed Rabea, Sebastiani, Giada, Poovorawan, Yong, Al Mahtab, Mamun, Pericàs, Juan M., Reverbel da Silveira, Themis, Hegyi, Peter, Azaz, Amer, Isa, Hasan M., Lertudomphonwanit, Chatmanee, Farrag, Mona Issa, Nugud, Ahmed Abd Alwahab, Du, Hong-Wei, Qi, Ke-Min, Mouane, Nezha, Cheng, Xin-Ran, Al Lawati, Tawfiq, Fagundes, Eleonora D.T., Ghazinyan, Hasmik, Hadjipanayis, Adamos, Fan, Jian-Gao, Gimiga, Nicoleta, Kamal, Naglaa M., Ștefănescu, Gabriela, Hong, Li, Diaconescu, Smaranda, Li, Ming, George, Jacob, and Zheng, Ming-Hua

Published
2024
Full Text
View/download PDF

20. Sex and ethnic disparities in hepatitis B evaluation and treatment across the world

Author

Kudaravalli, Sahith, Huang, Daniel Q., Yeh, Ming-Lun, Trinh, Lindsey, Tsai, P.C., Hsu, Yao-Chun, Kam, Leslie Y., Nguyen, Vy H., Ogawa, Eiichi, Lee, Dong Hyun, Ito, Takanori, Watanabe, Tsunamasa, Enomoto, Masaru, Preda, Carmen Monica, Ko, Michael K.L., Wan-Hin Hui, Rex, Atsukawa, Masanori, Suzuki, Takanori, Marciano, Sebastian, Barreira, Ana, Do, Son, Uojima, Haruki, Takahashi, Hirokazu, Quek, Sabrina X.Z., Toe Wai Khine, Htet Htet, Ishigami, Masatoshi, Itokawa, Norio, Go, Min Seok, Kozuka, Ritsuzo, Marin, Raluca Ioana, Sandra, Irina, Li, Jiayi, Zhang, Jian Q., Wong, Christopher, Yoshimaru, Yoko, Vo, Dang K.H., Tseng, Cheng-Hao, Lee, Chul-jin, Inoue, Kaori, Maeda, Mayumi, Hoang, Joseph K., Chau, Angela, Chuang, Wan-Long, Dai, Chia-Yen, Huang, Jee-Fu, Huang, Chung-Feng, Buti, Maria, Tanaka, Yasuhito, Gadano, Adrian Carlos, Yuen, Man-Fung, Cheung, Ramsey, Lim, Seng Gee, Trinh, Huy N., Toyoda, Hidenori, Yu, Ming-Lung, and Nguyen, Mindie H.

Published
2024
Full Text
View/download PDF

22. An international multidisciplinary consensus statement on MAFLD and the risk of CVD

Author

Zhou, Xiao-Dong, Targher, Giovanni, Byrne, Christopher D., Somers, Virend, Kim, Seung Up, Chahal, C. Anwar A., Wong, Vincent Wai-Sun, Cai, Jingjing, Shapiro, Michael D., Eslam, Mohammed, Steg, Philippe Gabriel, Sung, Ki-Chul, Misra, Anoop, Li, Jian-Jun, Brotons, Carlos, Huang, Yuli, Papatheodoridis, George V., Sun, Aijun, Yilmaz, Yusuf, Chan, Wah Kheong, Huang, Hui, Méndez-Sánchez, Nahum, Alqahtani, Saleh A., Cortez-Pinto, Helena, Lip, Gregory Y. H., de Knegt, Robert J., Ocama, Ponsiano, Romero-Gomez, Manuel, Fudim, Marat, Sebastiani, Giada, Son, Jang Won, Ryan, John D., Ikonomidis, Ignatios, Treeprasertsuk, Sombat, Pastori, Daniele, Lupsor-Platon, Monica, Tilg, Herbert, Ghazinyan, Hasmik, Boursier, Jerome, Hamaguchi, Masahide, Nguyen, Mindie H., Fan, Jian-Gao, Goh, George Boon-Bee, Al Mahtab, Mamun, Hamid, Saeed, Perera, Nilanka, George, Jacob, and Zheng, Ming-Hua

Published
2023
Full Text
View/download PDF

24. Sex Differences in Treatment Response to Nucleos(t)ide Therapy in Chronic Hepatitis B: A Multicenter Longitudinal Study

Author

Chau, Angela, Yeh, Ming-Lun, Tsai, Pei-Chien, Huang, Daniel Q., Kim, Sung Eun, Trinh, Huy, Yoon, Eileen L., Oh, Hyunwoo, Jeong, Jae Yoon, Ahn, Sang Bong, An, Jihyun, Tseng, Cheng-Hao, Hsu, Yao-Chun, Jeong, Soung Won, Cho, Yong Kyun, Shim, Jae-Jun, Kim, Hyoung Su, Ito, Takanori, Marciano, Sebastián, Kawashima, Keigo, Suzuki, Takanori, Watanabe, Tsunamasa, Nozaki, Akito, Ishikawa, Toru, Inoue, Kaori, Eguchi, Yuichiro, Uojima, Haruki, Abe, Hiroshi, Takahashi, Hirokazu, Chuma, Makoto, Ishigami, Masatoshi, Hoang, Joseph K., Maeda, Mayumi, Huang, Chung-Feng, Gadano, Adrian, Dai, Chia-Yen, Huang, Jee-Fu, Tanaka, Yasuhito, Chuang, Wan-Long, Lim, Seng Gee, Cheung, Ramsey, Yu, Ming-Lung, Jun, Dae-Won, and Nguyen, Mindie H.

Published
2024
Full Text
View/download PDF

34. Performance of Noninvasive Tests of Fibrosis Among Asians, Hispanic, and non-Hispanic Whites in the STELLAR Trials

Author

Wong, Vincent Wai-Sun, Tak, Won Young, Goh, George Boon Bee, Cheng, Pin-Nan, Lawitz, Eric J., Younossi, Zobair M., Vuppalanchi, Raj, Younes, Ziad, Alkhouri, Naim, Wang, Lulu, Liu, Jialuo, Kersey, Kathryn, Myers, Robert P., Harrison, Stephen A., Goodman, Zachary, Trauner, Michael, Romero-Gomez, Manuel, Anstee, Quentin M., Nguyen, Mindie H., and Okanoue, Takeshi

Published
2023
Full Text
View/download PDF

36. Effectiveness of entecavir vs tenofovir disoproxil fumarate for functional cure of chronic hepatitis B in an international cohort

Author

Hsu, Yao-Chun, Jun, Dae Won, Peng, Cheng-Yuan, Yeh, Ming-Lun, Trinh, Huy, Wong, Grace Lai-Hung, Kim, Sung Eun, Chen, Chien-Hung, Oh, Hyunwoo, Lin, Chia-Hsin, Trinh, Lindsey, Wong, Vincent Wai-Sun, Yoon, Eilleen, Ahn, Sang Bong, Huang, Daniel, Cho, Yong Kyun, Jeong, Jae Yoon, Jeong, Soung Won, Kim, Hyoung Su, Xie, Qing, Liu, Li, Riveiro-Barciela, Mar, Tsai, Pei-Chien, Accarino, Elena Vargas, Toyoda, Hidenori, Enomoto, Masaru, Preda, Carmen, Marciano, Sebastián, Hoang, Joseph, Huang, Chung-Feng, Kozuka, Ritsuzo, Yasuda, Satoshi, Istratescu, Doina, Lee, Dong-Hyun, Su, Jia-Ying, Huang, Yen-Tsung, Huang, Jee Fu, Dai, Chia-Yen, Chuang, Wan-Long, Yuen, Man-Fung, Gadano, Adrian, Cheung, Ramsey, Lim, Seng Gee, Buti, Maria, Yu, Ming-Lung, and Nguyen, Mindie H.

Published
2022
Full Text
View/download PDF

38. Contributors

Author

Agarwal, Kosh, primary, Armandi, Angelo, additional, Berná, Genoveva, additional, Boon-Bee Goh, George, additional, Bugianesi, Elisabetta, additional, Chan, Esther W., additional, Chan, Jacky C.H., additional, Cheung, Ka Wang, additional, Choi, Won-Mook, additional, Choi, Jonggi, additional, Cornejo, Andrea, additional, Crowley, Claire, additional, Dan, Yock Young, additional, Degré, Delphine, additional, Deltenre, Pierre, additional, Falade-Nwulia, Oluwaseun, additional, Fan, Jian-Gao, additional, Feng, Yi Bin, additional, Ferenci, Peter, additional, Fernández Gómez, Miguel, additional, Fromme, Malin, additional, Grønbæk, Lisbet, additional, Grønbæk, Henning, additional, Harisinghani, Mukesh, additional, Indolfi, Giuseppe, additional, Inoue, Takako, additional, Jang, Jeong Won, additional, Kew, Guan Sen, additional, Kim-Jun Teh, Kevin, additional, Kim, Min, additional, Kjær, Mikkel Breinholt, additional, Kornerup, Linda Skibsted, additional, Lara Romero, Carmen, additional, Lee, Sung Won, additional, Lee, Soon Kyu, additional, Lim, Young-Suk, additional, Liu, Chieh, additional, Liu, Chun-Jen, additional, Lok, James, additional, López Bermudo, Lucía, additional, Mak, Lung-Yi, additional, Méndez-Sánchez, Nahum, additional, Moreno, Christophe, additional, Muthiah, Mark, additional, Nam, Heechul, additional, Nartey, Yvonne A., additional, Nepal, Pankaj, additional, Nguyen, Mindie H., additional, Nicastro, Emanuele, additional, Ogawa, Eiichi, additional, Pawlotsky, Jean-Michel, additional, Pelusi, Serena, additional, Pik-Eu Chang, Jason, additional, Plauth, Mathias, additional, Romero-Gómez, Manuel, additional, Ronzoni, Luisa, additional, Seto, Mimi Tin-Yan, additional, Shi, Yi-Wen, additional, Shih, Yi-Fen, additional, Sridhar, Siddharth, additional, Stockdale, Alexander J., additional, Strnad, Pavel, additional, Tanaka, Yasuhito, additional, Teschke MD, Rolf, additional, Tucker, Joseph D., additional, Valenti, Luca, additional, Veloz, Maria Fernanda Guerra, additional, Yuen, Man-Fung, additional, Zhang, Cheng, additional, Zhao, Jiaxi, additional, and Zhou, Kali, additional

Published
2023
Full Text
View/download PDF

39. 2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis

Author

Le, Michael H., Yeo, Yee Hui, Li, Xiaohe, Li, Jie, Zou, Biyao, Wu, Yuankai, Ye, Qing, Huang, Daniel Q., Zhao, Changqing, Zhang, Jie, Liu, Chenxi, Chang, Na, Xing, Feng, Yan, Shiping, Wan, Zi Hui, Tang, Natasha Sook Yee, Mayumi, Maeda, Liu, Xinting, Liu, Chuanli, Rui, Fajuan, Yang, Hongli, Yang, Yao, Jin, Ruichun, Le, Richard H.X., Xu, Yayun, Le, David M., Barnett, Scott, Stave, Christopher Donald, Cheung, Ramsey, Zhu, Qiang, and Nguyen, Mindie H.

Published
2022
Full Text
View/download PDF

43. AGA Clinical Practice Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation in At-Risk Individuals.

Author

Ali, Faisal S., Nguyen, Mindie H., Hernaez, Ruben, Huang, Daniel Q., Wilder, Julius, Piscoya, Alejandro, Simon, Tracey G., and Falck-Ytter, Yngve

Abstract

Hepatitis B reactivation (HBVr) can occur due to a variety of immune-modulating exposures, including multiple drug classes and disease states. Antiviral prophylaxis can be effective in mitigating the risk of HBVr. In select cases, clinical monitoring without antiviral prophylaxis is sufficient for managing the risk of HBVr. This clinical practice guideline update aims to inform frontline health care practitioners by providing evidence-based practice recommendation for the management of HBVr in at-risk individuals. The Grading of Recommendations Assessment, Development and Evaluation framework was used to assess evidence and make recommendations. The panel conducted a systematic evidence review to identify new studies since publication of the first version of this clinical practice guideline in 2014. The Evidence to Decision framework was used to develop recommendations regarding the role of antiviral prophylaxis and monitoring without antiviral prophylaxis for management of HBVr. Clinical recommendations were based on the balance between desirable and undesirable effects, patient values, costs, and health equity considerations. The panel agreed on 4 recommendations. Based on evidence and baseline risk assessment, the panel made a strong recommendation in favor of antiviral prophylaxis for individuals at high risk of HBVr. For individuals at moderate risk of HBVr, a conditional recommendation was made in favor of antiviral prophylaxis. For individuals at low risk of HBVr, a conditional recommendation was made in favor of monitoring alone without antiviral prophylaxis. Monitoring should be performed at 1- to 3-month intervals, and must include assessment of hepatitis B viral load in addition to assessment of alanine aminotransferase. For individuals deemed to be at-risk of HBVr, the panel agreed on a strong recommendation in favor of testing for HBV; given universal Centers for Disease Control and Prevention screening guidance for hepatitis B for all adults 18 years and older by testing for HBV surface antigen, hepatitis B surface antibody, and total hepatitis B core antibody, stratifying screening practices by magnitude of HBVr risk is no longer needed. This document provides updated guidance for the management of HBVr in at-risk individuals. Limitations and gaps in the evidence are highlighted. This guideline is expected to require updating in 5 years from publication. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

44. Changes in Serum Rheumatoid Factor Following Eradication of Hepatitis C Virus Infection With Interferon or Direct Antiviral Therapy.

Author

Tsai, Ying‐Nan, Lo, Jamie Chieh, Tseng, Cheng‐Hao, Hsieh, Song‐Chou, Chiu, Wen‐Chin, Tai, Chi‐Ming, Chang, Chi‐Yang, Lee, Fu‐Jen, Nguyen, Mindie H., Lin, Jaw‐Town, and Hsu, Yao‐Chun

Subjects
HEPATITIS C, RHEUMATOID factor, HEPATITIS C virus, SEROCONVERSION, AUTOANTIBODIES
Abstract

Hepatitis C virus (HCV) infection is associated with a myriad of extrahepatic manifestations (EHM), as well as the production of autoantibodies, including rheumatoid factor (RF). This study aims to elucidate whether serum levels of RF change before and after HCV eradication, and whether these changes differ according to the type of therapy used. This is a retrospective cohort study of adults with chronic HCV infection treated with interferon‐free or interferon‐based regimens. All patients had HCV viremia at baseline and documented sustained virological response (SVR) 12 or 24 weeks after completing treatment. We measured the serum levels of RF at baseline and at SVR‐12 or −24 to analyse the changes after eradication. This study enrolled 297 patients (median age, 59 years; female, 48.5%; cirrhosis, 16.8%). Among them, 78 (26.3%) were RF‐positive by qualitative serology at baseline. This number decreased to 49 (16.5%) at SVR‐12 or −24 (p < 0.001). Quantitatively, the median RF also decreased from 1.6 IU/mL (interquartile range [IQR], undetectable—15.8) to undetectable (IQR, undetectable—6.6 IU/mL) (p < 0.001). Significant reductions were observed in both groups. The proportion with RF seropositivity decreased from 24.3% to 15.4% (p = 0.001) in patients treated with interferon‐free agents (n = 214) and from 31.3% to 19.3% (p = 0.006) in patients treated with interferon‐based regimens (n = 83), without significant difference between two groups (p = 0.40). Serum RF decreased after HCV eradication, regardless of treatment regimen. Our findings suggest that HCV eradication may attenuate HCV‐related autoimmunity. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

45. Disease Progression for Histologic Diagnosis of Metabolic Dysfunction-Associated Steatotic Liver Disease in the Real-World: A Nationwide US Study.

Author

Zhang, Xinrong, Kam, Leslie Yeeman, Barnett, Scott D., Henry, Linda, Cheung, Ramsey, and Nguyen, Mindie H.

Subjects
LIVER biopsy, PROPENSITY score matching, DISEASE progression, HEPATOCELLULAR carcinoma, LIVER diseases
Abstract

Introduction: We compared clinical characteristics and outcomes in real-world metabolic dysfunction-associated steatotic liver disease (MASLD) patients with or without liver biopsy using a nationwide cohort in United States (USA) to fill in gaps in selection of biopsy patients. Methods: We conducted a retrospective cohort study of adult MASLD patients using Marketscan® Databases (1/2007–12/2021). Patients were categorized into those with or without liver biopsy during follow-up. Results: We analyzed 540,326 MASLD patients: 23,732 with and 516,594 without biopsy. Only 4% of MASLD patients received liver biopsy and biopsy rate decreased in the last 5 years (9.4%–3.6%). After 1:5 propensity score matching on baseline characteristics including age, sex, and comorbidities, a total of 23,731 patients with biopsy and 118,396 matched patients without biopsy were analyzed. The incidence per 1,000 person-years for hepatocellular carcinoma (HCC) was 0.22 versus 2.18, cirrhosis 29.75 versus 90.44, and hepatic decompensation 15.84 versus 28.25 compared patients with and without biopsy. In multivariable analysis, patients with biopsy had more than 9 times higher risk of developing HCC, 3 times higher risk of cirrhosis, and 78% higher risk of hepatic decompensation. In subgroup analysis, the association remained consistent when stratified by age (<50 and ≥50), sex, and diabetes mellitus. Predictors of having biopsy included age, metabolic diseases, and living in North central or Northeast of USA. Conclusion: These data can inform clinical patient management that biopsy patients likely represent a selected group at higher risk for disease progression, especially in clinical trials for MASLD therapies. Introduction: We compared clinical characteristics and outcomes in real-world metabolic dysfunction-associated steatotic liver disease (MASLD) patients with or without liver biopsy using a nationwide cohort in United States (USA) to fill in gaps in selection of biopsy patients. Methods: We conducted a retrospective cohort study of adult MASLD patients using Marketscan® Databases (1/2007–12/2021). Patients were categorized into those with or without liver biopsy during follow-up. Results: We analyzed 540,326 MASLD patients: 23,732 with and 516,594 without biopsy. Only 4% of MASLD patients received liver biopsy and biopsy rate decreased in the last 5 years (9.4%–3.6%). After 1:5 propensity score matching on baseline characteristics including age, sex, and comorbidities, a total of 23,731 patients with biopsy and 118,396 matched patients without biopsy were analyzed. The incidence per 1,000 person-years for hepatocellular carcinoma (HCC) was 0.22 versus 2.18, cirrhosis 29.75 versus 90.44, and hepatic decompensation 15.84 versus 28.25 compared patients with and without biopsy. In multivariable analysis, patients with biopsy had more than 9 times higher risk of developing HCC, 3 times higher risk of cirrhosis, and 78% higher risk of hepatic decompensation. In subgroup analysis, the association remained consistent when stratified by age (<50 and ≥50), sex, and diabetes mellitus. Predictors of having biopsy included age, metabolic diseases, and living in North central or Northeast of USA. Conclusion: These data can inform clinical patient management that biopsy patients likely represent a selected group at higher risk for disease progression, especially in clinical trials for MASLD therapies. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

48. Progression Rates by Age, Sex, Treatment, and Disease Activity by AASLD and EASL Criteria: Data for Precision Medicine

Author

Park, Jiyoon, Le, An K., Tseng, Tai-Chung, Yeh, Ming-Lun, Jun, Dae Won, Trinh, Huy, Wong, Grace L.H., Chen, Chien-Hung, Peng, Cheng-Yuan, Kim, Sung Eun, Oh, Hyunwoo, Kwak, Min-Sun, Cheung, Ka Shing, Toyoda, Hidenori, Hsu, Yao-Chun, Jeong, Jae Yoon, Yoon, Eileen L., Ungtrakul, Teerapat, Zhang, Jian, Xie, Qing, Ahn, Sang Bong, Enomoto, Masaru, Shim, Jae-Jun, Cunningham, Chris, Jeong, Soung Won, Cho, Yong Kyun, Ogawa, Eiichi, Huang, Rui, Lee, Dong-Hyun, Takahashi, Hirokazu, Tsai, Pei-Chien, Huang, Chung-Feng, Dai, Chia-Yen, Tseng, Cheng-Hao, Yasuda, Satoshi, Kozuka, Ritsuzo, Li, Jiayi, Wong, Christopher, Wong, Clifford C., Zhao, Changqing, Hoang, Joseph, Eguchi, Yuichiro, Wu, Chao, Tanaka, Yasuhito, Gane, Ed, Tanwandee, Tawesak, Cheung, Ramsey, Yuen, Man-Fung, Lee, Hyo-Suk, Yu, Ming-Lung, Kao, Jia-Horng, Yang, Hwai-I, and Nguyen, Mindie H.

Published
2022
Full Text
View/download PDF

50. Effect of sarcopenia on survival in patients with cirrhosis: A meta-analysis

Author

Tantai, Xinxing, Liu, Yi, Yeo, Yee Hui, Praktiknjo, Michael, Mauro, Ezequiel, Hamaguchi, Yuhei, Engelmann, Cornelius, Zhang, Peng, Jeong, Jae Yoon, van Vugt, Jeroen Laurens Ad, Xiao, Huijuan, Deng, Huan, Gao, Xu, Ye, Qing, Zhang, Jiayuan, Yang, Longbao, Cai, Yaqin, Liu, Yixin, Liu, Na, Li, Zongfang, Han, Tao, Kaido, Toshimi, Sohn, Joo Hyun, Strassburg, Christian, Berg, Thomas, Trebicka, Jonel, Hsu, Yao-Chun, IJzermans, Jan Nicolaas Maria, Wang, Jinhai, Su, Grace L., Ji, Fanpu, and Nguyen, Mindie H.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results